Raloxifene improves coronary perfusion, cardiac contractility, and myocardial metabolism in the ischemic heart: Role of phosphatidylinositol 3-kinase/Akt pathway

Journal of Cardiovascular Pharmacology

Volumn 43, Issue 6, 2004, Pages 821-829

  Ogita, Hisakazu ^a   Node, Koichi ^b   Asanuma, Hiroshi ^a   Sanada, Shoji ^a   Kim, Jiyoong ^c   Takashima, Seiji ^a   Minamino, Tetsuo ^a   Hori, Masatsugu ^a   Kitakaze, Masafumi ^c  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAGA UNIVERSITY   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Calcium activated potassium channel; Coronary circulation; Hormones; Nitric oxide; Signal transduction

Indexed keywords

ANTIESTROGEN; BRADYKININ; CALCIUM ACTIVATED POTASSIUM CHANNEL; CHARYBDOTOXIN; FULVESTRANT; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; WORTMANNIN;

ANAEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOG; EXTRACORPOREAL CIRCULATION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; DOGS; MYOCARDIAL CONTRACTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RALOXIFENE; SIGNAL TRANSDUCTION;

EID: 2542468791     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200406000-00012     Document Type: Article

References (34)

1. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117: 1016-1037.
2. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336:1769-1775.
3. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med. 1991;325:756-762.
4. Vargas R, Wroblewska B, Rego A, et al. Oestradiol inhibits smooth muscle cell proliferation of pig coronary artery. Br J Pharmacol. 1993; 109:612-617.
5. Judd HL, Meldrum DR, Deftos LJ, et al. Estrogen replacement therapy: indications and complications. Ann Intern Med. 1983;98:195-205.
6. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-613.
7. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
8. Schulman SP, Thiemann DR, Ouyang P, et al. Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina. J Am Coll Cardiol. 2002;39:231-237.
9. Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 1994;93:63-69.
10. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641-1647.
11. Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 1996;11:835-842.
12. Kauffman RF, Bensch WR, Roudebush RE, et al. Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator. J Pharmacol Exp Ther. 1997;280: 146-153.
13. Khovidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med. 1999;130:431-439.
14. Figtree GA, Lu Y, Webb CM, et al. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation. 1999;100:1095-1101.
15. Zoma WD, Baker RS, Clark KE. Coronary and uterine vascular responses to raloxifene in the sheep. Am J Obstet Gynecol. 2000;182:521-528.
16. Node K, Kitakaze M, Kosaka H, et al. Increased release of NO during ischemia reduces myocardial contractility and improves metabolic dysfunction. Circulation. 1996;93:356-364.
17. + channels in coronary vasodilation induced by 17β-estradiol in ischemic heart failure. FASEB J. 1997;11:793-799.
18. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389:753-758.
19. Pike AC, Brzozowski AM, Hubbard RE, et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 1999;18:4608-4618.
20. Haynes MP, Sinha D, Russell KS, et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res. 2000;87:677-682.
21. Simoncini T, Hafezi-Moghadam A, Brazil DP, et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000;407:538-541.
22. Aronica SM, Kraus WL, Katzenellenbogen BS. Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci U S A. 1994;91:8517-8521.
23. Gu Q, Moss RL. 17β-Estradiol potentiates kainate-induced currents via activation of the cAMP cascade. J Neurosci. 1996;16:3620-3629.
24. Lagrange AH, Ronnekleiv OK, Kelly MJ. Modulation of G protein-coupled receptors by an estrogen receptor that activates protein kinase A. Mol Pharmacol. 1997;51:605-612.
25. Ca channels by Gs alpha independent of phosphorylation by protein kinase A. Am J Physiol. 1993;265:H1460-H1465.
26. + channels by ritodrine hydrochloride in uterine smooth muscle cells from pregnant women. Eur J Pharmacol. 1994;288:45-51.
27. Ca channels in airway smooth muscle cells by endogenous protein kinase A. Am J Physiol. 1996;271: L100-L105.
28. Ogita H, Node K, Asanuma H, et al. Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart. J Am Coll Cardiol. 2002;40: 998-1005.
29. Nagao T, Vanhoutte PM. Hyperpolarization as a mechanism for endothelium-dependent relaxations in the porcine coronary artery. J Physiol. 1992;445:355-367.
30. + channels regulates coronary blood flow in ischemic myocardium. Circulation. 1997;95:1560-1567.
31. Ghanam K, Ea-Kim L, Javellaud J, et al. Involvement of potassium channels in the protective effect of 17β-estradiol on hypercholesterolemic rabbit carotid artery. Atherosclerosis. 2000;152:59-67.
32. Ca channels through a cGMP-dependent mechanism. Circ Res. 1995;77:936-942.
33. Zuckerman SH, Bryan N. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL). Atherosclerosis. 1996;126:65-75.
34. Simoncini T, Genazzani AR. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab. 2000;85:2966-2969.